Input Parameter Values, by Health State, Age, and Sex.

DCC indicates decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PR, peginterferon alfa-2a plus ribavirin; SVR, sustained virologic response; TVR, telaprevir; US, United States.
aAnnual probabilities of progression in METAVIR fibrosis score for patients with SVR and with no or mild fibrosis (F0–F2) were assumed to be zero, which was consistent with data reported in various published studies [18], [34], [35], [36].
bPatients in the TVR+PR arm of the model received TVR for a total of 12 weeks and peginterferon alfa-2a plus ribavirin for a total of 24 or 48 weeks (see Figure 1).
cPost-treatment costs for patients who did not achieve SVR represent incremental costs over those incurred by patients who achieved SVR. Therefore, the model assumed post-treatment costs for patients who achieved SVR were $0. These post-treatment costs do not include additional costs incurred by patients who progressed to DCC, HCC, or liver transplant, which are shown separately.
dConsistent with the clinical trial protocols, anemia was managed with ribavirin dose reductions; therefore, costs of epoetin alfa were excluded from the analysis.